Zanubrutinib maintenance after CAR-T therapy for non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests if taking zanubrutinib (a pill) after CAR-T cell therapy helps keep non-Hodgkin B-cell lymphoma from coming back. It is for people who have already had or will have CAR-T treatment and can continue with this oral medication as a maintenance step.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of non-Hodgkin B-cell lymphoma (a type of blood cancer).
- You have received or plan to receive CAR-T cell therapy (a treatment that uses your own immune cells) and are taking or starting zanubrutinib (a pill) to maintain the effect.
- You must have a platelet count (blood clotting cell level) of at least 50 x 10^9/L.
- You cannot be pregnant or breastfeeding, and must not plan to conceive within a year (for men and women).
- You must be able to understand the study and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
This study tests whether taking a pill called pirtobrutinib after CAR-T therapy can help keep your lymphoma from coming back. If you've already had CAR-T, this might offer extra protection.
This study tests a pill called zanubrutinib as a follow-up treatment for people with DLBCL (a type of blood cancer) who are too frail or older to receive more intensive chemotherapy but whose cancer has already shrunk after initial treatment. The goal is to see if this maintenance therapy helps keep the cancer in remission and improves outcomes.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.